Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men
The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Abstract
Both estrogens and androgens play important roles in skeletal development and maintenance in men. The relative importance of estrogens and androgens in male bone metabolism, however, remains undefined. Anastrozole is an oral aromatase inhibitor that decreases estrogen production and increases androgen production in men. Currently, anastrozole is being investigated as a potential agent for the treatment of hypogonadism in aging men. Because anastrozole lowers estrogen levels and raises androgen levels, its effect on bone metabolism is difficult to predict. To assess the effects of anastrozole on bone turnover, we randomized 37 elderly (ages 62-74) mildly hypogonadal men (serum testosterone <350 ng/dl) to receive either anastrozole 1 mg daily (n=12), anastrozole 1 mg twice weekly (n=11), or daily placebo (n=14) for 12 weeks. Serum gonadal steroid levels, serum and urine biochemical markers of bone turnover, serum osteoprotegerin, and total body bone mineral density were measured at baseline and week 12. Mean serum levels of total and bioavailable testosterone increased substantially in both treated groups. Specifically, mean +/- SD bioavailable testosterone levels increased from 99+/-31 ng/dl to 207+/-65 ng/dl in the group receiving 1 mg of anastrozole daily and from 115+/-37 ng/dl to 178+/-55 ng/dl in the subjects receiving 1 mg of anastrozole twice weekly ( p <0.001 vs placebo for both groups). Serum estradiol levels decreased modestly in both treated groups (from 26+/-8 pg/m…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Treatment with anastrozole daily for 6 months, however, did not result in a significant improvement compared with placebo [67].”
From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [67]
In the citing paper
“Results from the Leder trial reported no change in markers of bone turnover, despite greater mean reductions in estradiol”
From Challenges in Testosterone Measurement, Data Interpretation, and Methodological Appraisal of Interventional Trials (2016) · cites this paper as [125]
In the citing paper
“while Burnett-Bowie’s group identified significant reductions in bone mineral density with therapy.”
From Challenges in Testosterone Measurement, Data Interpretation, and Methodological Appraisal of Interventional Trials (2016) · cites this paper as [125]
In the citing paper
“Although one publication of men undergoing anastrozole therapy over a 3-month period demonstrated no significant change in markers of bone resorption, a subsequent 12-month study demonstrated direct radiologic evidence of bone mineral density loss despite unchanged markers of bone resorption.125, 126”
From Challenges in Testosterone Measurement, Data Interpretation, and Methodological Appraisal of Interventional Trials (2016) · cites this paper as [125]
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889 · cited 1×
“Furthermore, because estrogen replacement increases cardiovascular risk [28,29] and impairs cognitive function [30–32] in women, it is possible that aromatase inhibition may have unique benefits compared with traditional testosterone replacement in men in these areas as well.”
BackgroundLongitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men
Harman, S. M., Metter, E. J., Tobin, J. D., Pearson, J., & Blackman, M. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7219 · Cited by 2,760
Estrogen Resistance Caused by a Mutation in the Estrogen-Receptor Gene in a Man
Smith, E. P., Boyd, J., Frank, G. R., Takahashi, H., Cohen, R. M., Specker, B., Williams, T. C., Lubahn, D. B., & Korach, K. S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410203311604 · Cited by 2,471
Grady, D., Herrington, D., Bittner, V., Blumenthal, R., Davidson, M., Hlatky, M., Hsia, J., Hulley, S., Herd, A., Khan, S., et al. (2002) · JAMA · doi:10.1001/jama.288.1.49 · Cited by 1,930 · cited 1×
“Furthermore, because estrogen replacement increases cardiovascular risk [28,29] and impairs cognitive function [30–32] in women, it is possible that aromatase inhibition may have unique benefits compared with traditional testosterone replacement in men in these areas as well.”
BackgroundFeldman, H. A., Longcope, C., Derby, C. A., Johannes, C. B., Araujo, A. B., Coviello, A. D., Bremner, W. J., & McKinlay, J. B. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8201 · Cited by 1,861 · cited 1×
“As men age there is a slow, steady decline in gonadal androgen production leading to a high incidence of hypogonadism [1–4].”
BackgroundMorishima, A., Grumbach, M. M., Simpson, E. R., Fisher, C., & Qin, K. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.12.8530621 · Cited by 1,416 · cited 1×
“receptor-a gene or the aromatase gene are osteoporotic [51–53], and numerous epidemiological studies have reported associations between serum estradiol levels and BMD or fracture in adult men [54–62].”
BackgroundGRAY, A., FELDMAN, H. A., MCKINLAY, J. B., & LONGCOPE, C. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-5-1016 · Cited by 1,118 · cited 1×
“As men age there is a slow, steady decline in gonadal androgen production leading to a high incidence of hypogonadism [1–4].”
BackgroundRapp, S. R., Espeland, M. A., Shumaker, S. A., Henderson, V. W., Brunner, R. L., Manson, J. E., Gass, M. L. S., Stefanick, M. L., Lane, D. S., Hays, J., et al. (2003) · JAMA · doi:10.1001/jama.289.20.2663 · Cited by 930 · cited 1×
“Furthermore, because estrogen replacement increases cardiovascular risk [28,29] and impairs cognitive function [30–32] in women, it is possible that aromatase inhibition may have unique benefits compared with traditional testosterone replacement in men in these areas as well.”
BackgroundTestosterone Replacement in Older Hypogonadal Men: A 12-Month Randomized Controlled Trial
Sih, R. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.6.1661 · Cited by 922
Cited by
Manolagas, S. C. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0024 · Cited by 1,200
“males (11), especially because similar small differences do not seem to cause BMD differences in pre- or perimenopausal women (12).”
BackgroundEstrogens and androgens in skeletal physiology and pathophysiology
Almeida, M., Laurent, M. R., Dubois, V., Claessens, F., O'Brien, C. A., Bouillon, R., Vanderschueren, D., & Manolagas, S. C. (2017) · Physiological Reviews · doi:10.1152/physrev.00033.2015 · Cited by 860
Sex Steroid Actions in Male Bone
Vanderschueren, D., Laurent, M. R., Claessens, F., Gielen, E., Lagerquist, M. K., Vandenput, L., Börjesson, A. E., & Ohlsson, C. (2014) · Endocrine Reviews · doi:10.1210/er.2014-1024 · Cited by 327
A concise review of testosterone and bone health
Mohamad, N. V., Soelaiman, I.-N., & Chin, K.-Y. (2016) · Clinical Interventions in Aging · doi:10.2147/cia.s115472 · Cited by 292
Khera, M., Adaikan, G., Buvat, J., Carrier, S., El-Meliegy, A., Hatzimouratidis, K., McCullough, A., Morgentaler, A., Torres, L. O., & Salonia, A. (2016) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2016.10.009 · Cited by 177
Aromatase inhibitors in men: effects and therapeutic options
de Ronde, W., & de Jong, F. H. (2011) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-9-93 · Cited by 155
“In the studies published so far aromatase inhibition in men did not appear to be associated with adverse effects on bone in a number of studies [37,59,82,83], but in a more recent study a decrease of spine BMD was observed after one year of treatment of elderly men with anastrozole [84].”
Burnett-Bowie, S.-A. M., McKay, E. A., Lee, H., & Leder, B. Z. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0739 · Cited by 146
“Importantly, in our earlier short-term study (41), we also did not observe any change in BTM, but this study was not long enough to provide meaningful insight regarding the effect of aromatase inhibition on BMD.”
BackgroundResultSelf-citationLetrozole once a week normalizes serum testosterone in obesity-related male hypogonadism
Loves, S., Ruinemans-Koerts, J., & de Boer, H. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0663 · Cited by 141
Trost, L. W., & Mulhall, J. P. (2016) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2016.04.068 · Cited by 98
Emerging medication for the treatment of male hypogonadism
Corona, G., Rastrelli, G., Vignozzi, L., & Maggi, M. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.683411 · Cited by 93
“A recent study on the effects of another aromatase inhibitor, anastrazole, in elderly hypogonadal men showed only a modest decrease in mean estradiol levels in those who received daily dosing over 12 weeks despite an over 100% increase in the mean T levels [86].”
BackgroundThe Rationale for Banning Human Chorionic Gonadotropin and Estrogen Blockers in Sport
Handelsman, D. J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2569 · Cited by 90
“A similar increase in blood testosterone concentrations ranging from 5 to 20 nmol/liter is reported with aromatase inhibitors such as testolactone (58–60), exemestane (61), and anastrozole (62).”
BackgroundIndirect androgen doping by oestrogen blockade in sports
Handelsman, D. J. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.150 · Cited by 84
“Similar increases in blood testosterone concentrations ranging from 5 to 20 nmol L 1 are reported with aromatase inhibitors such as testolactone (Clark and Sherins, 1989; Raman and Schlegel, 2002; Zumoff et al., 2003), exemestane (Mauras et al., 2003) and anastrozole (Leder and Finkelstein, 2005).”
BackgroundTestosterone and the Male Skeleton: A Dual Mode of Action
Sinnesael, M., Boonen, S., Claessens, F., Gielen, E., & Vanderschueren, D. (2011) · Journal of Osteoporosis · doi:10.4061/2011/240328 · Cited by 85
Yarrow, J. F., McCoy, S. C., & Borst, S. E. (2010) · Steroids · doi:10.1016/j.steroids.2010.01.019 · Cited by 80
The Role of Estrogen Modulators in Male Hypogonadism and Infertility.
Rambhatla, A., Mills, J. N., & Rajfer, J. (2016) · PubMed · doi:10.3909/riu0711 · Cited by 78
Safety and efficacy of testosterone gel in the treatment of male hypogonadism
Basaria, S. S., & Lakshman, K. M. (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s4466 · Cited by 64
Pharmacological management of late-onset hypogonadism
Rastrelli, G., Maggi, M., & Corona, G. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1445969 · Cited by 44
“They have been evaluated in two [63,65] (osteocalcin, osteoprotegerin,”
BackgroundColleluori, G., Chen, R., Turin, C. G., Vigevano, F., Qualls, C., Johnson, B., Mediwala, S., Villareal, D. T., & Armamento-Villareal, R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00277 · Cited by 43
“Although these studies showed a significant improvement in hormonal profile, there was no amelioration in symptoms (12, 16, 17) and these trials have a quite short duration to detect changes in symptoms (12, 13).”
BackgroundRichardson, D., Goldmeier, D., Frize, G., Lamba, H., De Souza, C., Kocsis, A., & Scullard, G. (2007) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2007.00451.x · Cited by 39
Aromatase Activity and Bone Loss in Men
Merlotti, D., Gennari, L., Stolakis, K., & Nuti, R. (2011) · Journal of Osteoporosis · doi:10.4061/2011/230671 · Cited by 46
“, anastrozole 1 mg/day or less), or in case of borderline hypogonadism (testosterone levels less than 350 ng/dl), at least over a short-term period of treatment [74].”
BackgroundTreatment of hypogonadism: Current and future therapies
Thirumalai, A., Berkseth, K. E., & Amory, J. K. (2017) · F1000Research · doi:10.12688/f1000research.10102.1 · Cited by 36
Influence of Aromatase Inhibition on the Bone-Protective Effects of Testosterone
Beck, D. T., Yarrow, J. F., Beggs, L. A., Otzel, D. M., Ye, F., Conover, C. F., Miller, J. R., Balaez, A., Combs, S. M., Leeper, A. M., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2265 · Cited by 28
“Despite the aforementioned findings, aromatase inhibition produces somewhat inconsistent outcomes in older men, with some studies reporting no change in serum bone turnover markers((13)) and no reduction in BMD((14)) after AN administration (even with a 30% to 50% reduction in circulating E2).”
ResultEmerging medication for the treatment of male hypogonadism
Aydoğdu, A., & Swerdloff, R. S. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1226799 · Cited by 27
“There was a nonsignificant decrease in estradiol levels, but T levels significantly increased (nearly twofold) in all patients [88].”
BackgroundTherapeutic uses of aromatase inhibitors in men
de Ronde, W. (2007) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e328121aad2 · Cited by 26
Holland, A. M., Roberts, M. D., Mumford, P. W., Mobley, C. B., Kephart, W. C., Conover, C. F., Beggs, L. A., Balaez, A., Otzel, D. M., Yarrow, J. F., et al. (2016) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00238.2016 · Cited by 26
“In contrast, data from our laboratory indicate that AN co-administration does not inhibit the ability of supraphysiological testosterone to prevent ORX-induced elevations in visceral adiposity (4) in rodents, and others have reported that administration of AN alone does not alter body composition in men, perhaps becau…”
ResultEffects of Transdermal Testosterone Gel or an Aromatase Inhibitor on Prostate Volume in Older Men
Dias, J. P., Melvin, D. L., Shardell, M. D., Ferrucci, L., Chia, C. W., Gharib, M., Egan, J. M., & Basaria, S. S. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1111 · Cited by 24
Aromatase activity and bone loss
Gennari, L., Merlotti, D., & Nuti, R. (2011) · Advances in clinical chemistry · doi:10.1016/b978-0-12-387025-4.00006-6 · Cited by 26
Khera, M. (2016) · Urologic Clinics of North America · doi:10.1016/j.ucl.2016.01.004 · Cited by 17
Adult-onset hypogonadism: evaluation and role of testosterone replacement therapy
Davidiuk, A. J., & Broderick, G. A. (2016) · Translational Andrology and Urology · doi:10.21037/tau.2016.09.02 · Cited by 16
“Given its effect on E2, concern developed regarding bone health and bone mineral density, and data remains conflicted over the long-term effect on bone strength (16,17).”
BackgroundAromatase inhibitors in male: A literature review
Korani, M. (2022) · Medicina Clínica Práctica · doi:10.1016/j.mcpsp.2022.100356 · Cited by 17
Testosterone, estradiol and aromatase inhibitor therapy in elderly men
Leder, B. Z. (2007) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2007.05.018 · Cited by 9
Self-citationMatta, R. A., Farrag, H. M.-A., Saedii, A. A. F., & Abdelrahman, M. M. (2022) · The Aging Male · doi:10.1080/13685538.2022.2049744 · Cited by 5
Alternative Treatment Modalities for the Hypogonadal Patient
Trost, L. W., & Khera, M. (2014) · Current Urology Reports · doi:10.1007/s11934-014-0417-2 · Cited by 7
Dutta, D., Mohindra, R., Kumar, M., & Sharma, M. (2022) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_3_22 · Cited by 6
“RevMan 5.3 was used for comparing MD of the [10] & Leder 2005 [11] Anz”
BackgroundMethodInfluentialGraham, P. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.14.2347 · Cited by 4
Role of Estrogens and Androgens in Osteoporosis
Laurent, M. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65814-2 · Cited by 3
Adjunct Management of Male Hypogonadism
Bach, P. V., Najari, B. B., & Kashanian, J. A. (2016) · Current Sexual Health Reports · doi:10.1007/s11930-016-0089-7 · Cited by 3
Androgens and the Skeleton – Humans
Leder, B. Z. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374602-3.00026-2
Self-citationAlternate Therapies for Testosterone Replacement
Şerefoğlu, E. C., Gökçe, A., Hellstrom, W. J. G., & Guay, A. T. (2012) · Humana Press eBooks · doi:10.1007/978-1-62703-179-0_11
Osteopenic syndrome and diabetes mellitus in men. Review of literature
Близнюк, Я. О., & Кирилюк, М. Л. (2015) · Clinical endocrinology and endocrine surgery · doi:10.24026/1818-1384.2(50).2015.74895
“За участю ароматази андрогени трансформуються в естрогени й опосередковано через естрогенові рецептори впливають на кісткову тканину [9-11].”
Rastrelli, G., Maggi, M., & Corona, G. (2022) · doi:10.1093/med/9780198870197.003.0387
Androgens, Androgen Receptor, and Bone
Colucci, S. C., & Brunetti, G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11229-2
Matta, R. A., Farrage, H. M., Saedii, A. A. F., & Abdelrahman, M. M. (2021) · Research Square · doi:10.21203/rs.3.rs-951391/v1
Role of estrogens and androgens in osteoporosis
Laurent, M. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00041-8
Metadata
- Authors
- Leder, B. Z., & Finkelstein, J. S.
- Affiliations
- Massachusetts General Hospital (US)
- Corresponding author
- Leder, Benjamin Z.
- Venue
- Osteoporosis International
- Published
- 2005-04-23
- Volume
- 16
- Issue
- 12
- Pages
- 1487-1494
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- OpenAlex
- W2017930983
- Semantic Scholar
- 0d9c8160bde1b2e73e7bd92c06f1a5a75080cbd7
- Cited by
- 44
- References
- 78
- Citations by year
- 2024: 1 · 2022: 4 · 2021: 1 · 2020: 1 · 2019: 1 · 2018: 2 · 2017: 1 · 2016: 11 · 2015: 1 · 2014: 3 · 2012: 2
- FWCI
- 2.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Osteoporosis International (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K24DK002759)
- National Center for Research Resources (M01RR001066, K23RR016310, RR-1066)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- anastrozole, aromatase inhibitors, male hypogonadism, older men, bone metabolism, testosterone, estradiol, bone turnover markers, bone mineral density, osteoprotegerin, N-telopeptide, deoxypyridinoline, osteocalcin, androgen production, bone resorption, bone formation, hormone replacement therapy
- MeSH terms
- Anastrozole, Aged, Bone and Bones, Bone Resorption, Estradiol, Glycoproteins, Humans, Hypogonadism, Male, Nitriles, Testosterone, Triazoles, Biomarkers, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Aromatase Inhibitors, Osteoprotegerin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.